FAQ: Oncotelic Therapeutics' Joint Venture Sapu Nano Receives Approval for Phase 1 Breast Cancer Trial
Summary
What is the main announcement in this press release?
Oncotelic Therapeutics announced that its joint venture Sapu Nano has received approval from Australia’s Human Research Ethics Committee to begin enrolling patients in a Phase 1 clinical trial of Sapu003, an injectable form of Everolimus for breast cancer.
Why is this new injectable version of Everolimus significant?
The injectable version is significant because oral Everolimus has limited absorption of about 10%, while Sapu003 delivered intravenously allows full drug absorption into the bloodstream, potentially improving efficacy over the oral version.
How does Sapu003’s delivery technology work?
Sapu003 uses Sapu Nano’s Deciparticle technology to deliver Everolimus intravenously, enabling full drug absorption into the bloodstream compared to the limited absorption of the oral formulation.
What is the purpose of this Phase 1 clinical trial?
The Phase 1 trial will determine optimal dosing for future studies, including a potential Phase 3 trial, with the goal of providing longer-lasting disease control and improved outcomes for breast cancer patients.
Who is conducting this clinical trial?
The trial is being conducted by Sapu Nano, which is a joint venture through GMP Biotechnology Limited, with Oncotelic Therapeutics owning 45% of GMP Bio. The venture operates under the leadership of Oncotelic’s CEO, Dr. Vuong Trieu.
Where is the clinical trial taking place?
The trial has received approval from Australia’s Human Research Ethics Committee, indicating it will be conducted in Australia.
What is Oncotelic Therapeutics’ focus as a company?
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, particularly for high-unmet-need cancers and rare pediatric indications.
How can investors get more information about Oncotelic Therapeutics?
Investors can access the latest news and updates relating to OTLC in the company’s newsroom at https://ibn.fm/OTLC
What is the relationship between Oncotelic and Sapu Nano?
Sapu Nano is a joint venture through GMP Biotechnology Limited, with Oncotelic owning 45% of GMP Bio. The joint venture advances its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology therapeutics.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 220570